Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes

Abstract

Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor linagliptin, with its proven efficacy, low propensity for hypoglycemia, and weight neutrality, has been shown to improve glycemic control for patients who are not well controlled with metformin. As patients often have other comorbidities requiring pharmacotherapy, an increase in pill number, different prescribing frequencies, and timing of medications may adversely impact patients’ adherence. Studies have shown that treatment nonadherence contributes to increased morbidity, mortality, and healthcare cost. In the United States, the single-pill combination (SPC) of linagliptin/metformin is available in three strengths approved for twice-daily administration: 2.5/500 mg, 2.5/850 mg, and 2.5/1000 mg. The SPC has the potential to reduce pill burden and simplify patients’ treatment regimens, thereby promoting improved adherence and efficacy.

A facile nano-iron oxide sensor for the electrochemical detection of the anti-diabetic drug linagliptin in the presence of glucose and metformin

“…Addition of linagliptin, dipeptidyl peptidase-IV inhibitor, to metformin improves glycemic control. Various analytical techniques are applied for simultaneous determination of binary diabetes drugs mixture such as LG and MET mixture (Haak 2015) including HPLC with UV detector (Vemula et al 2015), LC-MS/MS (Abbas Moussa et al 2019), and UV-Vis diffuse reflectance spectroscopy (El-Bagary et al 2013). No electrochemical reported work applied for the determination of either the LG or our studied mixture, only voltammetric determination for MET (Brocks et al 2010).…”

Electrochemical design of a new nanosensor based on cobalt nanoparticles, chitosan and MWCNT for the determination of daclatasvir: a hepatitis C antiviral drug

“…DAC is used in the treatment of chronic hepatitis C genotype 3 infections, it hinders the HCV nonstructural protein NS5A. 1,2 Modern research proposes that it targets two steps of the viral replication route, allowing fast decline of HCV RNA. 1 Chitosan (Cs) is a natural cationic biopolymer of b-(1/4) linked 2-amino-deoxy-D-glucopyranese that has both hydroxyl groups which might be oxidized to -CHO or -COOH, and amino groups that provides lone pair electrons for metal ions.…”

Perfil Clínico-Laboratorial E Comprometimento Vascular Em Pacientes Com Diabetes Mellitus Tipo 2

“…Devido ao caráter crônico do DM, a maioria dos pacientes não consegue manter um bom controle glicêmico apenas com dieta controlada e exercícios físicos, necessitando de terapia medicamentosa. O tratamento com hipoglicemiantes orais é a primeira escolha para pacientes com DM2, contudo, se estes fármacos não forem suficientes para controlar a hiperglicemia, é necessário o uso de insulina (HAAK, 2015). A alta frequência de pacientes DM2 em uso de insulina neste estudo indica um controle glicêmico inadequado.…”